JRI 

Effect of Metformin on single girl with polycystic ovarian syndrome

Vol. 6, Issue 2, / April-June 2005
(pages 177-186)

Tahereh Nazari Corresponding Author
- Department of Obstet . and Gynecol , Yahyanejad Hospital, Babol Medical Sciences University, Babol, Iran
Roya Bayat
- Department of Obs & Gyn, Fatemeh Al- Zahra Hospital, Babol, Iran
Haydeh Samiee
- Department of Obstet . and Gynecol , Yahyanejad Hospital, Babol Medical Sciences University, Babol, Iran

Received: 4/1/2005 Accepted: 4/1/2005 - Publisher : Avicenna Research Institute

Related Articles
in Google Scholar
in PubMed

 

Other Format
pdfFull Text (En)
pdfFull Text (Fa)
pdfAbstract (En)
pdfAbstract (Fa)
pdfePUB (En)
pdfBibTeX
pdfRefMan
pdfEndNote
xmlPMC XML
online readerPMC Reader
online readerHBIs XML

 


Abstract

Introduction: Polycystic ovarian syndrome (PCOS) is one of the most common endocrine dis-eases in women. This syndrome is characterized by hyperandrogenism, an ovulation, infertility and obesity. The recognition of insulin resistance as a principle factor in the pathogenesis of polycystic ovarian syndrome (PCOS) has lead to the use of insulin-lowering agents, also called’ insulin-sensitizing drugs, for its treatment. The use of metformin in this syndrome is one of the therapeutic option. The patients with this syndrome had long term sequel such as infertility, endometrial and breast cancer and cardio vascular disease, it is necessary to evaluate the effect of metformin on this complication. Materials and Methods: The purpose of this study is to evaluate the role of metformin on clinical and Laboratory finding of single girl with polycystic ovarian syndrome. Between April 2001 to April 2002, 36 single girls who were considered to have clinical and sonographic find-ings of polycystic ovarian syndrome, were studied in Gynecology division of babol university of medical sciences they were treated with metformin 500 mg three times daily Hormonal assay (FSH, LH, DHEA, Testestrone, 17 OH progesterone, Estradiol) and biochemistry assay (TG, Cholestrol, HDL, LDL) and also clinical changes were monitored pre and post treatment. Results: After treatment with metformin significant decrease in weight(p=0.004), BMI (p= 0.006) was seen. After treatment TG(p=0.03), LDL(p=0.01) was lowed and HDL (p=0.003) was increased. Also we find a significant decrease in LH(p=0.006), Estradiol (p=0.005), DHEA (p=0.001) and Testostrone (p=0.001). Conclusion: Our results showed improvement in acne (P=0.02) and hirsotism (P=0.026). Our results showed remarkable effects of metformin in improvement of clinical and laboratory parameters. Therefore research of longer duration for effect of this drug would be necessary.


Keywords: Ovary, Metformin, Single girl, Hirsotism, Obesity, Irregular menstruation, Polycystic ovary syndrome


To cite this article:


References

  1. Speroff L., Glass R.H., Kase N.G., Clinical Gyneco-logy Endocrinology and Infertility. 6th LW & W Comp-any.1999;pp:505-10.
  2. MacDougal M.J., Tan S.L., Balen S.H., Jacobs U.S. A controlled study comparing patients with and without polycystic ovaries undergoing in vitro fertilisation. Hum Reprod.1993;8:233-7.
  3. Balen A.H. The pathogenesis of polycystic ovary synd-rome: the enigme unravels. Lancet.1999;354:966-7.
  4. Burghen G.A., Givens J.R., Kitabachi A.E. Correlation of hyperandrogenism with hyperinsulinism in polyc-ystic ovarian disease. J Clin Endocrinol Metab. 1980; 50:113-16.
  5. Dunaif A., Futterweit W., Segal K.R., Dobjansky A. Profound peripheral insulin resistance, independent of obesity, in the polycystic ovary syndrome. Diabetes. 1989; 38:1165-74.
  6. Harris M.I., Hadden W.C., Knowler W.C., Dennentt P.H., Prevalence of diabetes and impaired glucose tol-erance and plasma gucose levels in US population aged 67-74 yr. Diabetes.1987;36:523-34.
  7. Pasquali R., Casimiri F., Venturoli S. Insulin resistance in patients with polycysitc ovaries: its relationship to body weight and androgen levels. Acta Endocrinol. 1983;104.110-116.
  8. Ehermann D., Sturis J., Byrne M.M., Karrison T., Rosenfield R.L., Polonsky K.S. Insulin secretory def-ects in polycystic ovary syndrome. Relationship to insulin sensitivity and family histoty of non-insulin dependent diabetes mellitus. J Clin lnvest.1995;96: 520-7.
  9. Nestler J.E., Jakubowicz D.J. Decreases in ovarian cytochorme P450cl7a activity and serum free restos-terone after reduction of insulin secretion in polycystic ativity and serum free testosterone after feduction of insulin secrerion in polycystic ovary syn? N Engl J Med.1996;335-617-23.
  10. Velazquez E.M., Mendoza S., Hamer T., Sosa F., Glueck C.J. Merformin therapy in polycystic ovary syndrome reduces hyperinstilinemia, insulin resisrance, hyperandrogenemia, and systolic blood pressure, While facilitating normal menses and pregnancy. Metabolism. 1994;43:647-45.
  11. Velazquez E., Acosta A., Mendoza S.G. Menstural Cyclicity after Metromin therapy in polycystic oveary syndrome. Obstet Gynecol.1997;90:392-5.
  12. Crava J.C., Fimbel S., Lejeune H., Cugnardey N., Dechaud H., Pugeat M. Effects of diet and metfromin administration on sex hormone binding globulin, andr-ogens, and insulin in hirsute and obese women. J ClinEndoctinol Metab.1995;80:2057-62
  13. Moghetti P., Gasrello R., Negri C., et al. Merformin effecte on clinical features. Endocrine and merabolic profiles, and insulin sensitivity in polycystic ovary syn-drome: a randomized, double blind, placebo contro-lled 6-month trial. Followed by open, long-term clinical evaluation. J Clin Endocrinol Metab.2000;85: 139-749.
  14. Homburg R. Polycystic ovary syndrome. 2nd Edition. LW & W Company.2001;148.
  15. Nestler J.E., Jakubowicz D.S., Decreases in ovarian cytolhrome p 450 C 17a activity and serum free testes-trone after reduction of insulin secretion in polycyst-icovary syndrome N Engl 3 Med.1996;335:617-623.
  16. Velazquez E., Meudozaos Hamer- T., Metformin The-rapy in polysystic ovary syndrome. Reduces hyper-insulinemia insulin resistance, systolic blood pressure while facilitating normal menses and pregnancy, Meta-bolism.1994;43:647-654.
  17. Casmiri F., Bisscotti M., Gambineri S. Metformin im-proves insulin, body fat distribution, and androgen in obese women with and without the polycystic ovary syndrome. Int J Obestity (suppl 21)561,1997.
  18. Morin- Papunen L., Koivunen R., Ruokenon A. Met-formin therapy improves menstural pattern of endo-crine and metabolic effect in women with polycystic ovary syndrome. Fertil Steril.1998;69:696.
  19. Acbay O., Gondoy S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril. 1998;65:946-949.
  20. Ehrmaun D., Cavaghau M., Imperial J. Effect of met-formin on insulin resistance, action in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 1997;82:524-530.
  21. Diamanti Kandarakis E., Tsianateli T., Bergiele A. Therupeutic effect of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 1998;138:269-274.
  22. Crave J.C., Fimbels M. Lejelane H. Effect of diet and melformn adminstration on sex hormone-binding glo-bulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab.1995; 80:2057-2062.
  23. Kelly C.S., Gordon D., The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endo-crinol.2002;147(2):217-21.
  24. Kazerooni T., Dehghan-Kooshkyhazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovariane syndrome. Gynecol Endoc-rinol.2003; 17(1):51-96.
  25. Barbieri R.L. Metformin for the treatment of poly-cystic ovary syndrome. Obstet Gynecol.2003; 101 (4): 785-93.
  26. Pouloit M.C., Despres S.P., Lemieux S., Moorjani S., Premblay A., Nadeau A. Waist circumference and abd-ominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumu-lation and related cardiovascular risk in men and momen. Am J cardiol.1994;73:460.
  27. Morin Papunen L., Vauhkonen I., Ruokonen A., Tapa-nainen J.S. Metformin versus ethinyl estradiol cypro-terone Acetate in the treatment of nonobese women with polycystic ovary syndrome. Araudomized study. J Clin Endocrinol Metab.2003;88(1):148-56.
  28. Chou K.H., Capp E., Clinical and endocrine parame-ters in response to metformin in women with poly-cystic ovary syndrome. Horm Metab Res.2003;35(2): 86-91.
  29. Mansfield R., Galea R., Brincat M., Hole D., Mason H. Metformin has direct effects on human ovarian ste-roidogenesis. Fertil Steril.2003; 79(4):956-62.
  30. Vrbikova J., Hill M., Starka L., Vondra K. Prediction of the effect of metformin trearment in patients with polycystic ovary syndrome. Gynecol Obstet Invest. 2002;53(2):100-4.
  31. Kumari A.S., Haq A., Jaya sundaram R. Metformin monotherapy in lean women with polycystic ovary syndrome. Reprod Biomed.2005;10(1):100-4.

COPE
SID
NLM
AJMB
IJBMLE
IJBMLE

Home | About Us | Current Issue | Past Issues | Submit a Manuscript | Instructions for Authors | Subscribe | Search | Contact Us

"Journal of Reproduction & Infertility" is owned, published, and managed by Avicenna Research Institute .
Creative Commons License

This work is licensed under a Creative Commons Attribution –NonCommercial 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Journal of Reproductoin and Infertility (JRI) is a member of COMMITTEE ON PUBLICATION ETHICS . Verify here .

©2024 - eISSN : 2251-676X, ISSN : 2228-5482, For any comments and questions please contact us.